The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/110938

Please be advised that this information was generated on 2019-03-17 and may be subject to change.
Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem

Linda Kwakkenbos a,⁎, Wim G.J.M. van Lankveld a, Madelon C. Vonk b, Eni S. Becker c, Frank H.J. van den Hoogen a, Cornelia H.M. van den Ende a

a Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands
b Department of Rheumatology, Radboud University Nijmegen Medical Center, The Netherlands
c Behavioural Science Institute, Clinical Psychology, Radboud University Nijmegen, The Netherlands

Article info

Objective: The prevalence of depressive symptoms is high in patients with systemic sclerosis (SSc, scleroderma). This study was conducted to determine which disease-related and psychosocial factors are associated with depressive symptoms, independent of sociodemographic factors.

Methods: In total, 215 patients with SSc completed questionnaires on sociodemographics, physical functioning (HAQ-DI), pain (VAS), fatigue (CIS), psychosocial characteristics (CISS, ICQ, PRO, ASE, FoP-Q-SF) and depressive symptoms (CES-D). Disease characteristics (disease duration, disease subtype, modified Rodnan Skin Score) were collected. Hierarchical linear regression analyses were conducted to assess associations with depressive symptoms.

Results: The mean CES-D score was 12.9 (SD=9.7) and the prevalence of patients scoring ≥16 and ≥19 were 32.1% and 25.1%, respectively. The variance explained by sociodemographics and disease characteristics was negligible ($R^2 ≤ 0.09$). Fatigue and pain were independently associated with depressive symptoms ($R^2$ change=.35). After adding psychological factors ($R^2$ change=.21), satisfaction with social support, emotion-focused coping and helplessness were also significantly associated with depressive symptoms. Higher fear of progression was associated with more depressive symptoms ($P ≤ 0.01$), and appearance self-esteem showed a marginally significant association ($P = .08$).

Conclusion: Depressive symptoms were common in the present sample of patients with SSc and were independently associated with pain, fatigue, social support, emotion-focused coping, helplessness and fear of progression. Results suggest that, in addition to assessment of disease characteristics, attention should be given also to psychosocial factors found to be associated with depressive symptoms. For the development and trialling of psychological interventions, fear of progression could be an important target.

© 2011 Elsevier Inc. Open access under the Elsevier OA license.

Introduction

Psychological consequences in patients with rheumatic diseases are increasingly recognised. Many studies focus on patients with rheumatoid arthritis and other inflammatory rheumatic diseases. Recently, the literature on psychological problems in patients with systemic sclerosis (scleroderma, SSc) is growing [1]. However, much is still unknown about the psychological problems of patients with SSc and their relationship with the disease.

Systemic sclerosis is a rare connective-tissue disease, with an estimated prevalence of 8.9 per 100,000 adults in the Netherlands and an estimated incidence of .77 per 100,000 [2]. The disease is characterized by thickening of the skin as a result of fibrosis. Furthermore, SSc can lead to severe dysfunction and failure of almost any internal organ [3], and Raynaud’s phenomenon is common. Although there is considerable heterogeneity in SSc manifestation, it has serious consequences in many patients. SSc confers a high mortality risk, with standardized mortality ratios of 1.5 to 7.2 [4]. The presence of anti–topoisomerase I antibodies and internal organ involvement are important determinants of mortality [4]. No effective treatments are available yet, and existing treatments mainly focus on symptom reduction.

As a consequence of the disease, patients with SSc report impairments in their physical as well as mental health-related quality of life [5]. Fatigue and pain are often reported by patients with SSc [6,7] and SSc causes increased disability over time [8]. Elevated levels of depressive symptoms were observed in 35-65% of the patients with SSc [9].
Unlike most other rheumatic diseases, SSc is a potential life-threatening disease. Fear of progression of the disease (FoP) is often reported as a major concern for patients with SSc and is related to mental health in diverse medical conditions [6,7,10–13]. However, there are no studies examining the relationship of FoP and psychological distress in SSc.

SSc also differs from other rheumatic diseases in terms of the changes in appearance it may cause. Most affected parts are the face and hands [14]. Previous studies of body image satisfaction and appearance self-esteem (ASE) in patients with SSc suggest that changes in the hands, fingers and face are most relevant in predicting overall ASE [15,16]. Low appearance self-esteem is related to psychological variables [15–17], and it is suggested that ASE is a mediator of the relationship between skin thickening and psychological distress [16].

As of now, it is hard to come to a conclusion as to which factors are of importance and could be targeted in treating depressive symptoms in SSc patients. Previous studies examining variables related to depressive symptoms revealed varying results [18–22]. This is to some extent due to the fact that different concepts were included. Some studies report that SSc severity or physical functioning are associates of depressive symptoms [19,20], but this finding was not always replicated in other studies [18,21]. Some studies [18,21,22] included physical as well as psychological measures e.g., aspects of personality [18,22], adequacy of emotional or social support [18,21], and acceptance, and found these [21] to be independently associated with depressive symptoms. None of the previous studies included fear of progression and appearance self-esteem, which are both often found as highly distressing to patients with SSc [6,7,11,17].

For a more systematic approach, this study was conducted to determine the independent association of sociodemographic variables, health status and psychological variables with depressive symptoms, as was recommended in the review of depression in SSc by Thombs et al. [9]. Factors included were derived from literature on associations of depression as well as factors patients reported as distressing in previous studies (appearance self-esteem, fear of progression). Examining all these variables in one model might provide us with starting points for developing (interdisciplinary) interventions for patients with SSc and symptoms of depression.

Method

Patients and procedure

Data were collected in the baseline assessment of the cohort study “Psychological factors in scleroderma,” including patients with a definitive diagnosis of SSc according to the preliminary ARA classification criteria [23] under treatment in the Sint Maartenskliniek or Radboud University Medical Center Nijmegen, the Netherlands. The main objective of the cohort study is to determine which psychological variables (e.g., coping, cognitions, social support) predict psychological distress. Patients in the cohort study complete sets of physical and psychological questionnaires every 6 months over 3 years. Furthermore, a number of disease characteristics were assessed by a rheumatologist (e.g., modified Rodnan Skin Score (mRSS)). Exclusion criteria for participation in the cohort were a life expectancy of less than a year (because of the burden of the study), acute serious complications (e.g., acute renal crisis), severe psychiatric comorbidity (e.g., severe substance abuse, psychosis or dementia), other serious comorbidities (e.g., cancer) and insufficient knowledge of the Dutch language. The attending rheumatologist assessed whether a patient met one or more of the exclusion criteria based on clinical experience, using a checklist stating the exclusion criteria. Data on the reasons for exclusion for individual patients are not available. All eligible patients in both clinics were invited to participate in the study by their attending rheumatologist. After they read the written patient information, they had the opportunity to ask questions to their rheumatologist or the researcher. Informed consent was obtained before the patients completed their first questionnaire at home. The study was approved by the local medical ethical board (CMO 2008/109). In total, 279 patients were invited to participate, of whom 215 completed the baseline questionnaire (response rate 77.1%). Non-responders did not differ from responders regarding age and gender. Data were collected between June 2008 and February 2010.

Measures

Sociodemographics

The sociodemographic variables assessed were: age, sex, marital status, education and current employment status.

Disease characteristics

The attending rheumatologist assessed disease duration (time since onset of first non-Raynaud’s symptoms), SSc disease subtype (limited or diffuse), and mRSS. Furthermore, auto-antibodies (ANA, ACA, Anti-TOPO, Anti-RNP) were assessed to describe our sample.

Physical functioning

Patients completed the Dutch version of the Scleroderma Health Assessment Questionnaire (SHAQ). The SHAQ consists of the Health Assessment Questionnaire (HAQ) and Visual Analogue Scales measuring perceived severity of six disease symptoms. The Disability Index score consists of 20 items, measuring 8 dimensions of functioning (dressing and grooming, ability to get up, eating, walking, personal hygiene, reach, grip strength and activities). The score of each dimension ranges from 0 (best function) to 3 (worst function), and the mean of these scores can be calculated as an indicator of overall physical functioning (HAQ-DI) with higher scores depicting worse functioning. The HAQ was originally developed for use in rheumatoid arthritis [24] but has demonstrated good reliability and validity in patients with SSc [25].

Pain was assessed using a Visual Analogue Scale (VAS) of 10 cm, ranging from 0 (no pain) to 100 (severe pain).

Fatigue was assessed with the “subjective experience of fatigue” subscale of the Checklist Individual Strength [26]. This subscale consists of 8 items, scored on a 7-point Likert scale. Higher scores depict higher levels of fatigue. The CIS has shown to be valid and reliable across different settings [26].

Depressive mood

The Center for Epidemiologic Studies- Depression Scale (CES-D) was used to assess depressive mood. The CES-D was originally developed to measure depressive symptomatology in the general population [27]. Recently, the scale has shown to be a reliable and valid measure of depressive symptoms in patients with SSc [28]. The CES-D is a 20-item measure, with the frequency of each depressive symptom rated on a 4-point Likert scale ranging from 0 to 3 (“rarely or none of the time” to “most or all of the time”). A score of ≥ 16 on the CES-D is considered as the cut-off for possible depression [27], while the cut-off ≥ 19 is identified as the most accurate cut-off for identifying major depression in arthritis [29].

Social support was measured using the Personal Resources Questionnaire 85-Part2 (PRQ85) [30]. Part 2 of the PRQ85 consists of 25 items measuring the patient’s perceived level of social support. Items are scored on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). Higher scores on the PRQ85 depict greater availability of and satisfaction with social support. The questionnaire has shown to be reliable and valid in healthy adults [31]. Furthermore, some support for the validity of the PRQ85 in patients with SSc was provided by Moser et al. [32].

Coping strategies were assessed using the Coping Inventory Stressful Situations (CISS) [33]. The CISS consists of 48 items, measuring...
three coping strategies: problem-focused coping, emotion-focused coping and avoidance. Items are scored on a 5-point Likert scale, ranging from 1 (not at all) to 5 (very much). The CISS showed good psychometric properties in diverse samples [33,34].

Disease cognitions were measured using the Illness Cognition Questionnaire (ICQ) [34]. The ICQ consists of 18 items, measuring helplessness, acceptance and disease benefits. Participants rate their agreement with the statements on a 4-point Likert scale, ranging from 1 (not at all) to 4 (completely). Higher scores on subscales reflect higher levels of agreement with that particular illness cognition. The scale has excellent construct and internal validity in chronic diseases [35]. In this study we only used the subscales acceptance and helplessness.

Satisfaction with appearance was measured using the 6-item subscale ‘Appearance self-esteem’ of the State Self Esteem Scale [36]. The items are scored from 1 (not at all) to 5 (extremely). Higher scores depict more satisfaction with appearance. A previous study in patients with SSc using this questionnaire demonstrated good internal consistency reliability [16].

Fear of progression was measured using the Short Form of the Fear of Progression Questionnaire (FoP-Q) [12]. The FoP-Q was developed to measure the fear of disease progression in patients with chronic illnesses. The original questionnaire comprises 43 items. The Short Form is a 12-item measure based on the FoP-Q. Each item is scored from 1 (never) to 5 (very often). The reliability and validity of the FoP-Q-SF in patients with breast cancer appears to be good [13]. As far as we know, this questionnaire was not previously used in patients with SSc.

All questionnaires showed good internal consistency in our sample, Cronbach’s α ranging from .77–.92.

Statistical analysis

Descriptive statistics are provided as means and standard deviations (SD) for continuous variables and percentages for categorical variables. Univariate associations of all sociodemographic and study variables with depressive symptoms were calculated. Hierarchical multiple regression analyses were conducted to determine the associations of the disease-related stressors with depressive mood. CES-D scores were used as the dependent variable. The independent variables were entered in the regression equation in five steps. Following the model of Thombs et al. [20], step 1 contained demographics (age, sex) and step 2 contained socioeconomic status (education, married/cohabitation). In step three, disease characteristics were added (limited/diffuse disease, disease duration, mRSS). Step 4 consisted of physical functioning variables (HAQ, pain, fatigue). In the fifth step, psychological variables were added (disease cognitions, social support, coping, appearance self-esteem, fear of progression). We chose to include all psychological variables to-
Table 2
Hierarchical regression analyses of demographics, disease status and psychological variables associated with depressive symptoms (CES-D, range 0–60).

<table>
<thead>
<tr>
<th>Step</th>
<th>Variable</th>
<th>B</th>
<th>[95% CI]</th>
<th>P</th>
<th>Beta Total R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1) Demographics</td>
<td>Age</td>
<td>−0.05</td>
<td>[−0.16, 0.06]</td>
<td>0.33</td>
<td>—0.16</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>−3.35</td>
<td>[−3.00, 1.28]</td>
<td>0.02</td>
<td>−0.16</td>
</tr>
<tr>
<td>Step 2) Socioeconomic status</td>
<td>Age</td>
<td>−0.07</td>
<td>[−0.19, 0.04]</td>
<td>0.21</td>
<td>−0.09</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>−3.06</td>
<td>[−5.84, −0.27]</td>
<td>0.03</td>
<td>−0.15</td>
</tr>
<tr>
<td></td>
<td>Higher education</td>
<td>−1.42</td>
<td>[−4.18, 1.35]</td>
<td>0.31</td>
<td>−0.07</td>
</tr>
<tr>
<td></td>
<td>Married/Cohabitating</td>
<td>−3.92</td>
<td>[−6.97, −0.88]</td>
<td>0.01</td>
<td>−0.17</td>
</tr>
<tr>
<td>Step 3) Disease characteristics</td>
<td>Age</td>
<td>−0.18</td>
<td>[−0.21, 0.04]</td>
<td>0.20</td>
<td>−0.10</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>−3.95</td>
<td>[−6.93, −0.97]</td>
<td>0.01</td>
<td>−0.19</td>
</tr>
<tr>
<td></td>
<td>Higher education</td>
<td>−1.41</td>
<td>[−4.32, 1.50]</td>
<td>0.34</td>
<td>−0.07</td>
</tr>
<tr>
<td></td>
<td>Married/Cohabitating</td>
<td>−3.76</td>
<td>[−7.00, −0.32]</td>
<td>0.02</td>
<td>−0.16</td>
</tr>
<tr>
<td></td>
<td>Limited disease</td>
<td>−0.95</td>
<td>[−4.40, 2.50]</td>
<td>0.59</td>
<td>−0.04</td>
</tr>
<tr>
<td></td>
<td>Disease duration</td>
<td>0.04</td>
<td>[−1.31, 0.41]</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>mRSS</td>
<td>0.22</td>
<td>[0.03, 0.47]</td>
<td>0.09</td>
<td>0.13</td>
</tr>
<tr>
<td>Step 4) Physical functioning</td>
<td>Age</td>
<td>−0.08</td>
<td>[−0.18, 0.02]</td>
<td>0.13</td>
<td>−0.09</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>−1.42</td>
<td>[−3.89, 1.06]</td>
<td>0.26</td>
<td>−0.07</td>
</tr>
<tr>
<td></td>
<td>Higher education</td>
<td>−0.92</td>
<td>[−3.30, 1.45]</td>
<td>0.44</td>
<td>−0.04</td>
</tr>
<tr>
<td></td>
<td>Married/Cohabitating</td>
<td>−2.48</td>
<td>[−5.08, 1.12]</td>
<td>0.06</td>
<td>−0.11</td>
</tr>
<tr>
<td></td>
<td>Limited disease</td>
<td>0.87</td>
<td>[1.93, 3.67]</td>
<td>0.54</td>
<td>−0.04</td>
</tr>
<tr>
<td></td>
<td>Disease duration</td>
<td>0.03</td>
<td>[−1.11, 0.17]</td>
<td>0.71</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>mRSS</td>
<td>0.11</td>
<td>[−0.10, 0.32]</td>
<td>0.32</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>HAQ score</td>
<td>−0.52</td>
<td>[−2.45, 1.41]</td>
<td>0.60</td>
<td>−0.04</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>0.06</td>
<td>[0.01, 0.12]</td>
<td>0.03</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>0.44</td>
<td>[3.48, 4.44]</td>
<td>0.01</td>
<td>0.15</td>
</tr>
<tr>
<td>Step 5) Psychosocial factors ¹</td>
<td>Age</td>
<td>−0.04</td>
<td>[−0.12, 0.05]</td>
<td>0.37</td>
<td>−0.05</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>−0.86</td>
<td>[−3.00, 1.28]</td>
<td>0.43</td>
<td>−0.04</td>
</tr>
<tr>
<td></td>
<td>Higher education</td>
<td>−0.37</td>
<td>[−2.42, 1.69]</td>
<td>0.73</td>
<td>−0.02</td>
</tr>
<tr>
<td></td>
<td>Married/Cohabitating</td>
<td>−2.0</td>
<td>[−4.41, 4.41]</td>
<td>0.11</td>
<td>−0.09</td>
</tr>
<tr>
<td></td>
<td>Limited disease</td>
<td>−0.04</td>
<td>[−2.38, 2.31]</td>
<td>0.98</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>Disease duration</td>
<td>0.02</td>
<td>[−1.10, 0.14]</td>
<td>0.74</td>
<td>−0.02</td>
</tr>
<tr>
<td></td>
<td>mRSS</td>
<td>0.08</td>
<td>[−0.10, 0.26]</td>
<td>0.41</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>HAQ score</td>
<td>−1.16</td>
<td>[−2.95, 0.52]</td>
<td>0.20</td>
<td>−0.08</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>0.05</td>
<td>[0.00, 0.10]</td>
<td>0.05</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>0.23</td>
<td>[1.33, 3.33]</td>
<td>0.01</td>
<td>0.31</td>
</tr>
<tr>
<td></td>
<td>Social support</td>
<td>−0.03</td>
<td>[−1.22, −0.17]</td>
<td>0.01</td>
<td>−0.14</td>
</tr>
<tr>
<td></td>
<td>Helplessness</td>
<td>0.19</td>
<td>[0.04, 0.75]</td>
<td>0.03</td>
<td>0.17</td>
</tr>
<tr>
<td></td>
<td>Acceptance</td>
<td>0.06</td>
<td>[−2.67, 2.71]</td>
<td>0.69</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>Problem-focused coping</td>
<td>−0.03</td>
<td>[−1.12, 0.07]</td>
<td>0.62</td>
<td>−0.03</td>
</tr>
<tr>
<td></td>
<td>Emotion-focused coping</td>
<td>0.18</td>
<td>[0.08, 0.28]</td>
<td>0.01</td>
<td>0.23</td>
</tr>
<tr>
<td></td>
<td>Avoidance coping</td>
<td>0.06</td>
<td>[0.05, 0.16]</td>
<td>0.30</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>Appearance self esteem</td>
<td>−0.23</td>
<td>[−0.49, 0.03]</td>
<td>0.08</td>
<td>−0.10</td>
</tr>
<tr>
<td></td>
<td>Fear of progression</td>
<td>0.20</td>
<td>[0.05, 0.34]</td>
<td>−0.01</td>
<td>0.18</td>
</tr>
</tbody>
</table>

* Final model.
* P-value for the change in variance accounted for (ΔR²) ≤ 0.05.
** P-value for the change in variance accounted for (ΔR²) ≤ 0.001.

Discussion

This study assessed the independent association of sociodemographic, disease, and psychosocial variables, including appearance self-esteem and fear of progression, with depressive symptoms. Depressive symptoms were prevalent in our sample, comparable to those in previous studies [21,28], as was the percentage of patients scoring above the cut-offs for possible and probable depression (32.1% and 25.1%, respectively) [9].

Significant correlates of depressive symptoms were found, in addition to pain and fatigue, mostly in the psychological domain. Depressive symptoms were associated with lower satisfaction with social support, emotion-focused coping, helplessness and higher fear of progression. The variance explained by the sociodemographic measures and disease characteristics assessed in the present study was negligible. Therefore, it is recommended that, in addition to assessment of physical functioning, attention should be paid to pain, fatigue and psychological factors found to be associated with depressive symptoms. A recent study of patients with rheumatoid arthritis showed that long-term patterns of depression are associated with worse function and perceptions of poor health [40]. Appropriate and timely treatment of depressive symptoms might therefore contribute to an improvement in health outcomes, also for patients with SSc.

To our knowledge, this is the first study that included appearance self-esteem and fear of progression as correlates of depression, in addition to sociodemographics, disease characteristics and physical functioning. Body image concerns as well as fear of the future were identified as important psychological stressors in patients with SSc in many existing studies [6,7,10,11]. Moreover, the present study suggests they both are independently associated with depressive symptoms, although the association of appearance self-esteem with depressive symptoms should be interpreted with caution since it was only marginally significant. More research is needed to confirm our findings on appearance self-esteem.

An important finding from this study was that fear of progression is associated with depression. Because SSc is a serious and potentially life-threatening disease, disease progression is a real concern for most patients. However, although fear of progression may have some basis in reality, patients could overestimate their fear of progression in comparison to the likelihood of actual progression. Decreasing this dysfunctional fear to a more functional level might lead to fewer depressive symptoms and an increased quality of life. A recent study showed that two short psychotherapeutic group interventions in cancer patients were effective in reducing fear of progression in the long term [41]. The authors also found significant improvements in depression, anxiety and health-
related quality of life. Since, in the present study, fear of progression showed a higher association with depressive symptoms than actual indicators of the likelihood of progression (disease type, disease duration, mRSS), this could be an important target of intervention in patients with SSc as well. As of now, it is not clear whether this finding is unique for patients with SSc, or if it is also true for patients with other chronic diseases (like rheumatoid arthritis), for which fear of progression might play an important role as well.

Ideally, psychological interventions for depressive symptoms in SSc should be integrated into interdisciplinary care, taking levels of fatigue and pain into account. Solving sleep problems or changing unhelpful coping behaviour could help patients decrease fatigue levels. In addition, exercises matched to patients’ physical abilities could help increase physical condition and reduce fatigue.

Since this study was cross-sectional, no causal relationships could be established. Longitudinal research is needed to identify which factors predict the development of depressive symptoms over time. This study could however be a starting point in determining which variables to include in longitudinal studies. Another limitation is that not all possible physical consequences of SSc were included in the present study. For example, the involvement of specific organs was not taken into account. Furthermore, the use of self-report measures is a limitation of this study. Beyond the lack of validation studies concerning Dutch versions of the instruments used (including the CES-D), in SSc, method overlap can inflate associations between depression scores and other self-report measures. Patients with depressive symptoms might respond to the other self-report measures in a more negative manner as well. Another limitation of the use of self-report measurements in this study is that the association of helplessness and fatigue with depressive symptoms could partly be explained by the fact that both are an important characteristic of depression. Helplessness as used in this study is a cognitive concept, and therefore might have overlapped with the learned helplessness in depression. A recent study by Thoms et al. [42] showed that, although patients with SSc had inflated scores on the somatic items of the CES-D compared to matched controls, this had no substantial impact on the overall score of the measure. Also, the sensitivity analysis omitting fatigue revealed only a minor difference in the variance explained in the final model.

Strengths of the present study were that data were collected in a relatively large and well-defined sample of patients and that a number of physical and psychological variables were examined in a standardized way. All variables were included in the model without preselection, providing us with a precise and valid insight to variables that are independently associated with depressive symptoms. The patients included in the study are comparable with the large Dutch sample in a recent study by Vonk et al. [2] with regard to disease characteristics and demographics, except that our sample included slightly more men, indicating that results are generalizable.

In conclusion, depressive symptoms were common in the present study of patients with SSc and were independently associated with pain, fatigue, social support, emotion-focused coping, helplessness and fear of progression. Results suggest that, in addition to assessment of disease characteristics, attention should be given also to psychosocial factors found to be associated with depressive symptoms. For the development and trialling of psychological interventions, fear of progression could be an important target.

Acknowledgements

There was no financial support or other benefits from commercial sources funding the work reported in the manuscript. We would like to thank Linda Willems, MSc for her help with data entry and Drs. Ing. Pierre Souren for his help with the statistical analyses.

References


Hale ED, Treharne GJ, Kitas GD. The common-sense model of self-regulation of health and illness: how can we use it to understand and respond to our patients’ needs. Rheumatology 2007;46:904–6.


